Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
110.10
+2.85 (2.66%)
At close: Oct 31, 2025, 4:00 PM EDT
107.90
-2.20 (-2.00%)
After-hours: Oct 31, 2025, 7:54 PM EDT
Spruce Biosciences Revenue
Spruce Biosciences had revenue of $1.30M in the twelve months ending June 30, 2025, down -86.43% year-over-year. In the year 2024, Spruce Biosciences had annual revenue of $4.91M, down -51.32%.
Revenue (ttm)
$1.30M
Revenue Growth
-86.43%
P/S Ratio
48.34
Revenue / Employee
$61,857
Employees
21
Market Cap
62.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.91M | -5.18M | -51.32% |
| Dec 31, 2023 | 10.09M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| Eli Lilly and Company | 59.42B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
SPRB News
- 26 days ago - Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade) - Seeking Alpha
- 26 days ago - This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug. - Barrons
- 27 days ago - Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
- 6 weeks ago - Spruce Biosciences Resumes Trading on the Nasdaq Capital Market - Business Wire